Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023.
Yang J, Hyeon S, Baek JY, Kang MS, Lee KY, Lee YH, Huh K, Cho SY, Kang CI, Chung DR, Peck KR, Won G, Lee HW, Kim K, Hwang I, Lee SY, Kim BC, Lee YK, Ko JH.
Yang J, et al. Among authors: lee sy, lee yh, lee hw, lee ky, lee yk.
J Korean Med Sci. 2023 Jul 10;38(27):e205. doi: 10.3346/jkms.2023.38.e205.
J Korean Med Sci. 2023.
PMID: 37431539
Free PMC article.